State of Alaska Department of Revenue lifted its stake in shares of Becton Dickinson and Co (NYSE:BDX) by 99.8% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 81,048 shares of the medical instruments supplier’s stock after buying an additional 40,479 shares during the period. State of Alaska Department of Revenue’s holdings in Becton Dickinson and were worth $17,347,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently made changes to their positions in BDX. Beach Investment Management LLC. purchased a new position in shares of Becton Dickinson and during the second quarter valued at about $2,218,000. State Board of Administration of Florida Retirement System increased its position in shares of Becton Dickinson and by 0.7% during the second quarter. State Board of Administration of Florida Retirement System now owns 312,941 shares of the medical instruments supplier’s stock valued at $61,058,000 after buying an additional 2,242 shares during the period. Wayne Hummer Investments L.L.C. purchased a new position in shares of Becton Dickinson and during the second quarter valued at about $220,000. Knowledge Leaders Capital LLC increased its position in shares of Becton Dickinson and by 0.7% during the second quarter. Knowledge Leaders Capital LLC now owns 31,169 shares of the medical instruments supplier’s stock valued at $6,081,000 after buying an additional 226 shares during the period. Finally, Boston Private Wealth LLC increased its position in shares of Becton Dickinson and by 9.2% during the second quarter. Boston Private Wealth LLC now owns 21,166 shares of the medical instruments supplier’s stock valued at $4,130,000 after buying an additional 1,789 shares during the period. Institutional investors own 75.54% of the company’s stock.

Shares of Becton Dickinson and Co (BDX) opened at $232.12 on Friday. The firm has a market cap of $53,250.00, a PE ratio of 49.92, a price-to-earnings-growth ratio of 1.76 and a beta of 1.07. The company has a quick ratio of 5.03, a current ratio of 5.58 and a debt-to-equity ratio of 1.44. Becton Dickinson and Co has a fifty-two week low of $169.19 and a fifty-two week high of $232.35.

Becton Dickinson and (NYSE:BDX) last posted its quarterly earnings results on Thursday, November 2nd. The medical instruments supplier reported $2.40 EPS for the quarter, beating the Zacks’ consensus estimate of $2.37 by $0.03. Becton Dickinson and had a net margin of 8.52% and a return on equity of 20.56%. The firm had revenue of $3.17 billion for the quarter, compared to analysts’ expectations of $3.14 billion. During the same quarter in the prior year, the company posted $2.12 earnings per share. The business’s revenue for the quarter was down 2.0% on a year-over-year basis. equities analysts expect that Becton Dickinson and Co will post 10.66 EPS for the current year.

The company also recently declared a quarterly dividend, which was paid on Friday, December 29th. Stockholders of record on Friday, December 8th were issued a dividend of $0.75 per share. This is a boost from Becton Dickinson and’s previous quarterly dividend of $0.73. The ex-dividend date of this dividend was Thursday, December 7th. This represents a $3.00 dividend on an annualized basis and a dividend yield of 1.29%. Becton Dickinson and’s dividend payout ratio is presently 64.52%.

A number of equities research analysts have weighed in on BDX shares. Bank of America started coverage on shares of Becton Dickinson and in a report on Friday. They issued a “buy” rating on the stock. Zacks Investment Research upgraded shares of Becton Dickinson and from a “hold” rating to a “buy” rating and set a $259.00 price objective on the stock in a report on Friday. Stifel Nicolaus restated a “buy” rating and issued a $245.00 price objective on shares of Becton Dickinson and in a report on Friday, November 3rd. Royal Bank of Canada restated a “sector perform” rating and issued a $230.00 price objective (up previously from $210.00) on shares of Becton Dickinson and in a report on Friday, November 3rd. Finally, Morgan Stanley upped their price objective on shares of Becton Dickinson and from $205.00 to $245.00 and gave the stock an “equal weight” rating in a report on Friday, November 3rd. Four analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the stock. Becton Dickinson and currently has a consensus rating of “Buy” and a consensus target price of $231.47.

COPYRIGHT VIOLATION WARNING: This piece of content was originally posted by TheOlympiaReport and is the property of of TheOlympiaReport. If you are viewing this piece of content on another website, it was stolen and republished in violation of international copyright and trademark laws. The correct version of this piece of content can be read at https://theolympiareport.com/2018/01/19/becton-dickinson-and-co-bdx-shares-bought-by-state-of-alaska-department-of-revenue.html.

Becton Dickinson and Company Profile

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).

Institutional Ownership by Quarter for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.